Items with tag "diagnostics"

News

MDx Health's SelectMDx to be Distributed Across Middle East by IPS Genomix

MDx Health gains market access of the Middle East via partner IPS Genomix.

Read more

Biocartis and A*STAR's ETPL initiate development of breast cancer assay to guide therapy selection

Singapore's Agency for Science, Technology and Research will develop the new assay while Biocartis will be responsible for commercialisation.

Read more

MDxHealth Launches AssureMDx for Bladder Cancer Liquid Biopsy Test

Methylation specialist MDx Health brings its third assay to the market. The AssureMDx liquid biopsy assay is able to detect bladder cancer in a urine sample.

Read more

Unchained Labs acquires Trinean

The Belgian developer of the DropSense system Trinean is being acquired by American lab devices developer Unchained Labs.

Read more

Biocartis launches CE-marked IVD test for lung cancer

Biocartis, an innovative molecular diagnostics company, today announced the CE-marking of the Idylla™ EGFR Mutation Test, as such achieving an important milestone in Biocartis' lung cancer menu. T…

Read more

MDxHealth Launches CE-Marked SelectMDx IVD PCR Kit and UrNCollect Device for prostate cancer

MDx Health has launched its new prostate cancer test. SelectMDx is designed to detect prostate cancer in urine samples, avoiding painful prostate biopsies when cancer is suspected.

Read more

Biocartis collaborates with MRC Technology in development of breast cancer liquid biopsy test

Together with MRC Technology, Biocartis has announced a collaboration for the development of a liquid biopsy test for hormone treatment-resistant breast cancer.

Read more

Biocartis launches CE-marked IVD NRAS test for colorectal cancer

To also serve geographies where BRAF testing is not reimbursed, Biocartis launches a new NRAS test next to their combined NRAS-BRAF assay.

Read more

Innovative software Moon autonomously diagnoses rare diseases within minutes

Diploid, a Leuven-based genomics startup, announces the release of Moon, the first software package that autonomously diagnoses rare diseases using artificial intelligence. Moon reduces the time f…

Read more

BIOCARTIS ANNOUNCES ITS NEW CEO

Biocartis has revealed its pick for its vacant top function.

Read more

Characterising the profile of metastatic breast cancer for improved treatment

Researchers at the Jules Bordet Institute - Université libre de Bruxelles, VIB and KU Leuven recently published an important study offering a better understanding of the progression of breast canc…

Read more

Liquid Biopsy is Cost-Effective for Biopsy Selection in prostate cancer

MDxHealth today announced BJU International published a study demonstrating that its SelectMDx for Prostate Cancer test can reduce overdiagnosis and overtreatment of men at risk of prostate cancer…

Read more

Biocartis opens doors in the US and appoints US General Manager

Biocartis opens doors in the US and appoints US General Manager Vishal Sikri to delegate outrol of Idylla in the states.

Read more

Licensing and collaboration deal for MDx Health and Ghent University

MDx Health and Ghent University have signed licensing and collaboration agreements for the development of biomarker visualisation technology in prostate and bladder cancer.

Read more

Non-invasive colorectal cancer screening test

VIB and DNAlytics are proud to announce their partnership to develop a data-driven, high-performance and non-invasive Colorectal Cancer screening test, the ColonoKit.

Read more

Biocartis receives grant for development of a fully automated MSI test

Belgian diagnostics producer receives grant from Flemish government to develop microsatellite instability (MSI) test in collaboration with VIB-KULeuven. Not only will the test offer prognosis esti…

Read more

Biocartis CEO steps down, company announces strong 2016 results

In a press release stating strong annual results for the cancer diagnostic producer, Biocartis also announced a change in its top management position. Its current CEO, Rudi Pauwels, has expressed …

Read more

MDxHealth Awarded US Department of Veterans Affairs Contract for ConfirmMDx Testing

MDxHealth today announced that it has been awarded a US Government Services Administration (GSA) supply contract to use ConfirmMDx for Prostate Cancer within the Department of Veterans Affairs (VA…

Read more

MDx Health ConfirMDx test covered by new insurance group

MDxHealth Announces Horizon Blue Cross Blue Shield of New Jersey Issues Positive Coverage Policy on ConfirmMDx. The decision provides access to more than 3.8 million members.

Read more

Novosanis closes third round of seed funding

Novosanis announced today it has closed a new round of financing. The share capital was increased by a combined effort from current investor Taste Invest and from the Novosanis management team. Th…

Read more

MDxHealth Announces Preliminary Update on 2016 Results and Appointment of CFO

MDxHealth SA today provides a preliminary update on its year-end results, reporting that it expects to achieve its upgraded market guidance for full-year 2016 financial results following continued…

Read more

New Familial Mediterranean Fever Diagnostic Tool

Researchers at VIB and Ghent University have developed a tool to diagnose Familial Mediterranean Fever (FMF). Particularly common among Mediterranean populations, this genetic disease is character…

Read more

Biocartis' mini-lab soon available on US market

Biocartis granted rights to Thermo Fisher Scientific to distribute its rapid and fully automated molecular diagnostics Idylla platform in the US, including its accompanying assays, with a first fo…

Read more

Good news after good news for Biocartis

After the Idylla test for lung cancer was recognized as best-in-class in a recent study, Biocartis also receives a € 2.5 million grant from the Flemish government. In a study comparing lung-ca…

Read more

ADx NeuroSciences teams up with Japanese partner

ADx NeuroSciences has signed a collaborative R&D agreement with the Japanese Nipro Corporation. The companies will jointly develop next-generation in vitro diagnostics for Alzheimer’s disease. The…

Read more

Biocartis takes on lung cancer

Biocartis ups its arsenal once again. This time, the company behind the diagnostic Idylla™ platform adds a lung cancer assay to its ever growing menu of diagnostic tests. Lung cancer comprises…

Read more

Afraid you might have an STD? Test it with DirectLab!

Saltro (Utrecht, NL) launched DirectLab, a webshop where anyone can buy lab tests online and anonymously. The first test available is a chlamydia test. With Saltro DirectLab, you are no longer dep…

Read more

Biocartis’ Ebola test approved for emergency use

The U.S. Food and Drug Administration (FDA) has granted Biocartis’ Ebola Virus Triage Test emergency use authorization. The test was developed in collaboration with Janssen Diagnostics and the Ins…

Read more

White Paper on In Vitro Diagnostics - Belgium: R&D hotspot

The BioVox Diagnostics White Paper presents a privileged insight into successful Belgian diagnostics companies. Download it for free! Six Belgian IVD experts discuss the challenges and opportu…

Read more

Biocartis - Merck partnership for colorectal cancer diagnostics

Biocartis closed a deal with Merck KGaA (Merck) for the development and commercialization of a new liquid biopsy RAS biomarker test for patients with metastatic colorectal cancer (mCRC). A patient…

Read more

Faster cancer diagnosis: new Idylla products

Biocartis launched two new products for cancer diagnosis to use with its molecular diagnostics platform Idylla™; a liquid biopsy test and a tissue biopsy test.  The first product, a ctBRAF Mut…

Read more

Fingernails for easy diabetes diagnostics

If it’s up to the University of Ghent, doctors soon won’t need blood anymore to detect diabetes. A piece of fingernail can be sufficient. “Especially for developing countries, this method is a…

Read more

Fast and easy tumor detection with liquid biopsy

VITO and the Antwerp University Hospital (UZA) recently joined forces with 3 Flemish companies, Biocartis, RIC and Pharmafluidics for the project ‘Early Diagnosis by Easy Sampling’. The consortium…

Read more

GlycoCirrho test predicts liver cancer

Researchers at the UZ Ghent have discovered that the GlycoCirrhoTest for the early detection of cirrhosis also accurately predicts the risk for the development of liver cancer. Their results are p…

Read more

€1.4 million for liquid biopsy to detect cancer

The IWT (Flemish Agency for Innovation by Science and Technology) granted 1,4 million euros to Biocartis to support the development of a liquid biopsy diagnostic test for melanoma and colorectal c…

Read more

Multiplicom launches non-invasive test to detect Down's

Multiplicom (Niel) launched a new non-invasive prenatal test (NIPT), Clarigo™, based on a blood sample. Genetic analysis of the baby’s DNA, which is present in the blood of the mother, enables the…

Read more

New test to diagnose prostate cancer with urine sample

MDxHealth (Herstal) announced today the launch of a new non-invasive, “liquid biopsy”, diagnostic test for prostate cancer using a urine sample. Initially, the test, named SelectMDx, is offered in…

Read more

Coris BioConcept launches new rapid diagnostic platform

Coris BioConcept, a Walloon company specializing in in vitro diagnostics launched a new rapid diagnostic platform. It uses a novel microfluidic technology to conduct analyzes in multiplex mode. Th…

Read more

FLUIDDA WINS PRESTIGIOUS BELCHAM AWARD FOR THE MOST PROMISING COMPANY OF THE YEAR IN NEW YORK

BELCHAM, the Belgian-American Chamber of Commerce in New York has awarded its annual series of prizes. The Antwerp lung specialist Fluidda was awarded as the most promising company of the year. …

Read more

Dutch company acquired by MDxHealth

The Dutch biotech company NovioGendix is acquired by the Belgian company MDxHealth. MDxHealth will pay $ 8.8 million (€ 7.8 million) for the Nijmegen-based company. NovioGendix is a spin-off of th…

Read more

Urine HPV screening

HPV is the most common sexually transmitted infection (1). While most infections are subclinical, two virus serotypes are known to be carcinogenic. The lack of symptoms and the discomfort associat…

Read more

Biocartis confirms Idylla sales and patient value

The first half year results of Biocartis confirm a successful expansion of Idylla™, Biocartis’ fully automated molecular diagnostics system. 114 instruments (up to June 30, 2015) have been sold to…

Read more

Roche acquires Biocartis’ competitor

Roche has paid 190 million dollar for the acquisition of GeneWEAVE (Los Gatos, CA), an American company that specializes in molecular diagnostics. GeneWEAVE’s shareholders even can receive 235 mil…

Read more

New test improves diagnosis of chronic lymphocytic leukemia

Chronic Lymphocytic Leukemia or CLL is the most common form of leukemia in adults and has a highly variable outcome. Patients experience prolonged periods of disease stabilization - the cancer is …

Read more

More screening options for breast and ovarian cancers

Multiplicom releases two new kits for the screening of hereditary breast and ovarian cancer. In addition to the tests for BRCA1 and BRCA2 released in 2012, Multiplicom’s novel assays include a com…

Read more

Got arthritis? DNAlytics has an app for it!

Approximately 30% of patients with undifferentiated arthritis develop rheumatoid arthritis - a chronic, inflammatory disease causing deformity of the affected joints. Depending on geographical loc…

Read more

Biocartis to present BRAF liquid biopsy data at ASCO

Biocartis (BCART), will today present liquid biopsy data from the BRAF mutation study at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The study, in collaboration wit…

Read more

Congrats to Biocartis!

The Mechelen-based biotech company Biocartis starts its IPO adventure. The demand for shares was 6,5 times higher than the offer. Biocartis gathered 100 million euros with an offer of 8,7 million …

Read more

Trinean wins 25.000 euro for disposables production

Trinean won the “Time for a Boost 2015” competition organized by Test and Measurement Solutions. CEO Kurt Hensen handed a cheque of 25 000 euro to the Ghent University spin-off. Trinean develo…

Read more

Insights

Diagnosing rare genetic conditions within minutes

Diagnosing rare genetic conditions within minutes

Moon is a new software package that, within minutes, diagnoses patients who suffer from rare diseases. All the software requires are the patient’s symptoms and sequencing data. Moon then applies a…

Read more

Watch out for Lyme disease!

Watch out for Lyme disease!

Summer is coming, it’s getting warmer, and you’re planning on outdoor activities. Unfortunately, ticks are getting out there as well, and your chances of being bitten are rising. Ticks can cause L…

Read more

Biocartis: ready for commercial boom

Biocartis: ready for commercial boom

Biocartis CSO Geert Maertens gives an overview of the progress and future prospects of the company.

Read more

STOP EYE-BALLING MRI SCANS

STOP EYE-BALLING MRI SCANS

Up to 1 billion people in the world suffer from neurological disorders. Currently, many brain scans are still evaluated by visual inspection. Quantification of different biomarkers in these brain …

Read more

MyCartis barcodes biological samples

MyCartis barcodes biological samples

MyCartis is an early-stage company that was founded in September 2014 when Pronota (Ghent, Belgium) and the Biocartis Evalution Business unit (Lausanne, Switzerland) joined forces.  This was an id…

Read more

A guinea pig: your perfect partner to produce monoclonal antibodies

A guinea pig: your perfect partner to produce monoclonal antibodies

SynAbs is a young UCL spin-off company, founded in September 2015 with the support of Walloon life science incubator WBC, UCL’s tech transfer office LTTO and the French investment group Biotech In…

Read more

Personalized Arthritis Medicine Saves Lots of Money

Personalized Arthritis Medicine Saves Lots of Money

Detecting arthritis early on is one of the key challenges facing rheumatology. However, some patients present with undifferentiated arthritis, meaning that it is not possible to establish a diagno…

Read more

Alzheimer's, ALS or a brain injury: ADx neurosciences knows how to tackle it

Alzheimer's, ALS or a brain injury: ADx neurosciences knows how to tackle it

ADx NeuroSciences might be described best as the Intel of biomarker assays for neuro-degenerative disease. They don’t create complete kits, but their top-notch biomaterials are included in the ass…

Read more

Coris Bioconcept diagnoses antibiotic resistance

Coris Bioconcept diagnoses antibiotic resistance

With almost 20 years of experience, Coris BioConcept knows the world of infectious disease diagnostics inside and out. Their straightforward chromatography-based assays for pathogen detection, whi…

Read more

Multiplicom: a strong focus on DNA analysis

Multiplicom: a strong focus on DNA analysis

Multiplicom offers molecular diagnostics products, focused on human genetics, oncology and prenatal testing. The company was built on a technology that came from the University of Antwerp and VIB…

Read more

KU Leuven students develop winning device to detect kidney failure

KU Leuven students develop winning device to detect kidney failure

A team of fourteen KU Leuven students has built a diagnostic device that can analyze the blood of kidney patients in five minutes. It’s a fast, inexpensive, portable alternative to the current slo…

Read more

The Center of Human Genetics reveals  all your secrets

The Center of Human Genetics reveals all your secrets

Have a cystic fibrosis or BRCA mutation, or maybe a dangerous variant of the Huntington’s gene  dangling in your cells? The Center of Human Genetics (CME) in Leuven will clear this out for you. As…

Read more

Diagnostics for better use of the healthcare budget

Diagnostics for better use of the healthcare budget

Developing a diagnostic test is one thing. Bringing it to the market while taking into account the product’s value for different stakeholders is a very different task. While clinicians might estim…

Read more

From Belgium to NYC and starting a 'super sniffer’ company

From Belgium to NYC and starting a 'super sniffer’ company

Charlotte D’Hulst left Belgium for a postdoc in NYC. Today she has two kids and lives in Brooklyn. Oh, and she founded a biotech company, MouSensor, LLC. Hard to resist the entrepreneurial buzz in…

Read more

Diagnosis on your smartphone!

Diagnosis on your smartphone!

Belgium’s first-ever mHealth Hackathon event took place in Brussels between March 18-20, 2016. Armed with breakthrough ideas and backed up by caffeine, competitive technology developers, scientist…

Read more

The Year of Biocartis

The Year of Biocartis

2015 was a truly eventful year for Biocartis. It was marked by many transitions, which some see as a prelude to the company becoming a globally active market leader. Biocartis saw the source of it…

Read more

RSV OR THE FLU? NOW YOU KNOW IT IMMEDIATELY

RSV OR THE FLU? NOW YOU KNOW IT IMMEDIATELY

Janssen Diagnostics has developed a molecular diagnostic test which will be used with the Biocartis’ Idylla™ platform, to determine Influenza and Respiratory Syncytial Virus (RSV) infections of th…

Read more

Biobanking: a vital asset for Belgium's scientific excellence

Biobanking: a vital asset for Belgium's scientific excellence

In 2014, three French-speaking universities of Belgium (UCL, ULB, ULg, in association with UMons and UNamur) joined forces, with the support of DG06, Innoviris and BioWin, to create the Biothèque …

Read more

Ebola diagnostics – faster, safer, and more accurate

Ebola diagnostics – faster, safer, and more accurate

“Last year the Ebola outbreak kick-started the development of a fast and accurate Ebola test to be used with Biocartis’ Idylla™ platform” - says Daap Kooij (Janssen Diagnostics). “We expect the te…

Read more

Idylla™ : a lab-in-a-box

Idylla™ : a lab-in-a-box

Janssen and Biocartis are collaborating in order to bring diagnostic  testing closer to the patients. To learn more about the future objectives of the Janssen – Biocartis partnership we are talkin…

Read more

Nuclear technology saves lives, especially in Belgium!

Nuclear technology saves lives, especially in Belgium!

Nuclear energy has become a part of our every day lives, but not solely for electricity production. Over the last century, nuclear technology has become increasingly important in health care. It a…

Read more

A user experience of Idylla™, the mini-lab

A user experience of Idylla™, the mini-lab

Idylla™, Biocartis’ fully automated molecular diagnostics system was launched in September 2014. Since then, over 100 units have been sold. We asked the very first customer, Prof. dr. Bart Neyns t…

Read more

MS slowly but surely unravels its secrets

MS slowly but surely unravels its secrets

Piet Stinissen is Professor and Dean at the Faculty of Medicine and Life Sciences at the University of Hasselt, where he is head of the Immunology and Biochemistry laboratory. He is a biochemist a…

Read more

VoltionRx detects colon cancer with a drop of blood

VoltionRx detects colon cancer with a drop of blood

Belgian Volition – a subsidiary of Volition Rx – is a life sciences company located in Namur (Belgium) focused on developing blood-based diagnostic tests for a broad range of cancer types and othe…

Read more

VC Views

Grail: A billion-dollar gamble?

Grail: A billion-dollar gamble?

Grail has vowed to change the field of cancer diagnostics via simple blood tests and ctDNA analysis. Their Big Data approach, in which the company will build an atlas of DNA found in the blood, co…

Read more

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Janssen UGent GSK Turnstone XpandInnovation V-Bio Ventures KU Leuven Biowin Itera Life Science Flanders.bio

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.